2010 soliris-eculizumab-342875 Drugs Drugs eculizumab 2003 /viewarticle/941970 Journal Article immediately and vaccines are administered less than two weeks before starting Soliris therapy. c Special situations for MenB include those receiving a complement inhibitor (eg, eculizumab). 2.2 Recommended Dosage Regimen – PNH For patients 18 years of age and older, Soliris therapy consists of: SOLIRIS should be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological, renal or neuromuscular disorders. Both medications work by blocking the activity of the C5 protein, which is part of the complement cascade. SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica.In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Do not administer as an IV Push or Bolus Injection. Soliris is given through an infusion into a vein (intravenous, IV). It is created by eHealthMe based on reports of 48,909 people who have side effects while taking Soliris from the FDA, and is updated regularly. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–7. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. The newborn had no evidence of infections, a possible side effect of Soliris. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil J. With Soliris, A future with fewer relapses is possible. Overall, this case report suggests that Soliris’ use … Initially, infusions are given weekly for 4 weeks, followed by a fifth dose 1 week later. Paroxysmal nocturnal hemoglobinuria (PHN) • 600 mg weekly for the first 4 weeks, followed by • 900 mg for the fifth dose 1 week later, then • 900 mg every 2 weeks thereafter. The main difference between the two is that Ultomiris, a newer medication, is more stable and lasts longer in the body, so it needs to be administered less frequently — every two months, as opposed to every two weeks with Soliris. Soliris ® (eculizumab), a complement inhibitor, is the first and only medication approved by the FDA to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. Soliris is only administered as an intravenous infusion. Soliris is a therapy given through an intravenous infusion (IV) usually over 35 minutes. Accessed 6/2017. b For MenB-FHbp, if dose 2 was administered at least 6 months after dose 1, dose 3 is not needed. Counterfeit drug administered is reported only by a few people who take Soliris. The amount of Soliris that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition you have. Soliris ® (eculizumab) product label pdf icon [33 pages] external icon. An extra dose of Soliris was administered 24 hours postpartum to the mother, and she then resumed infusions every two weeks. Then ongoing infusions are given every 2 weeks. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early. The phase IV clinical study analyzes which people take Soliris and have Counterfeit drug administered. Atypical hemolytic uremia syndrome (aHUS) … Healthcare professionals who prescribe Soliris must enroll in the Soliris REMS [see Warnings and Precautions (5.2)]. Dosing occurs in two phases.